Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Carbamazepine Prescribing

Carbamazepine Prescribing A genetic test should be used to identify patients of Asian ancestry who may be at a higher risk of rare but serious skin reactions when taking medications containing carbamazepine, according to updated product labeling announced by the US Food and Drug Administration. Carbamazepine, which is used in the treatment of epilepsy, bipolar disorder, and neuropathic pain, has been associated with severe and sometimes life-threatening skin conditions such as toxic epidermal necrolysis and Stevens-Johnson syndrome. The risk of such reactions in predominantly white populations is small, with about 1 to 6 in 10 000 new users experiencing a serious skin reaction. Previous labels of the drug have warned of this risk. But in some Asian countries the risk of these reactions is 10 times greater. A gene variant found almost exclusively in individuals of Asian ancestry, HLA-B* 1502, has been linked to such severe skin reactions. Blood tests can be used to identify this variant, allowing physicians to avoid using the drug in patients who have the greatest risk of these events. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Carbamazepine Prescribing

Kuehn, Bridget M.
JAMA , Volume 299 (4) – Jan 30, 2008
Download PDF
1 page

Carbamazepine Prescribing

Abstract

A genetic test should be used to identify patients of Asian ancestry who may be at a higher risk of rare but serious skin reactions when taking medications containing carbamazepine, according to updated product labeling announced by the US Food and Drug Administration. Carbamazepine, which is used in the treatment of epilepsy, bipolar disorder, and neuropathic pain, has been associated with severe and sometimes life-threatening skin conditions such as toxic epidermal necrolysis and...
Loading next page...
 
/lp/american-medical-association/carbamazepine-prescribing-O01EZVbG7K

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Medical Association
Copyright
Copyright © 2008 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2008.6
Publisher site
See Article on Publisher Site

Abstract

A genetic test should be used to identify patients of Asian ancestry who may be at a higher risk of rare but serious skin reactions when taking medications containing carbamazepine, according to updated product labeling announced by the US Food and Drug Administration. Carbamazepine, which is used in the treatment of epilepsy, bipolar disorder, and neuropathic pain, has been associated with severe and sometimes life-threatening skin conditions such as toxic epidermal necrolysis and Stevens-Johnson syndrome. The risk of such reactions in predominantly white populations is small, with about 1 to 6 in 10 000 new users experiencing a serious skin reaction. Previous labels of the drug have warned of this risk. But in some Asian countries the risk of these reactions is 10 times greater. A gene variant found almost exclusively in individuals of Asian ancestry, HLA-B* 1502, has been linked to such severe skin reactions. Blood tests can be used to identify this variant, allowing physicians to avoid using the drug in patients who have the greatest risk of these events.

Journal

JAMA – American Medical Association

Published: Jan 30, 2008

Keywords: carbamazepine,prescribing behavior

There are no references for this article.